Selected article for: "antigenic site and vaccine design"
Author: Jones, Harrison G.; Battles, Michael B.; Lin, Chun-Chi; Bianchi, Siro; Corti, Davide; McLellan, Jason S.
Title: Alternative conformations of a major antigenic site on RSV F
  • Document date: 2019_7_15
    • ID: 1r20hl2b_28
    Snippet: Recent characterization of the antibody repertoire against RSV F highlights the importance of prefusion-specific epitopes when selecting immunogens for RSV F vaccine design, particularly after the recent failure of several postfusion RSV F vaccine trials [16, 18, 32, 33, 61, 62] . Our findings demonstrate that potently neutralizing human antibodies that target antigenic site Ø can recognize a variety of alternative conformations and have varying.....
    Document: Recent characterization of the antibody repertoire against RSV F highlights the importance of prefusion-specific epitopes when selecting immunogens for RSV F vaccine design, particularly after the recent failure of several postfusion RSV F vaccine trials [16, 18, 32, 33, 61, 62] . Our findings demonstrate that potently neutralizing human antibodies that target antigenic site Ø can recognize a variety of alternative conformations and have varying degrees of subtype specificity. Because potent antibodies can bind to the various alternative conformations of site Ø, we propose that the ideal prefusion RSV F immunogen would maintain this natural conformational flexibility of site Ø as well as present neutralizing epitopes common to both RSV subtypes.

    Search related documents:
    Co phrase search for related documents
    • alternative conformation and conformational flexibility: 1
    • alternative conformation and human antibody: 1
    • antibody repertoire and human antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • antibody repertoire and potent antibody: 1, 2, 3, 4
    • antigenic site and conformational flexibility: 1, 2
    • antigenic site and human antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • antigenic site and potent antibody: 1, 2
    • antigenic site and prefusion specific epitope: 1
    • conformational flexibility and human antibody: 1
    • human antibody and potent antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • neutralize epitope and potent antibody: 1
    • potent antibody and prefusion specific epitope: 1
    • potent antibody and recent failure: 1